Clinical data on track for Q4 2025 from Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCExpansion…
Q1 2025 pharma services revenue of $2.1 million, at 62% gross marginThree of the top 10 U.S. transplant centers expected…
Announced Boehringer Ingelheim strategic collaboration and license agreement for CUE-501, including an upfront payment of $12 million and ~$345 million…
LOUISVILLE, Ky., May 12, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a…
Beyond Oil Receives C$2.166M in Warrant Exercise Proceeds from 1,836,766 WarrantsVANCOUVER, BC and KIBBUTZ YIFAT, Israel, May 12, 2025 (GLOBE…
Q1 revenue of $21.9 million, increasing 11% year-over-yearQ1 gross profit increased 9% year-over-year to $13.3 millionIncreases full year 2025 guidance to…
Year over year growth in Net Revenue and Gross ProfitLAS VEGAS, May 12, 2025 (GLOBE NEWSWIRE) -- HF Foods Group…
MARLBOROUGH, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced…
BDC-4182 Phase 1 dose-escalation study now open for enrollmentBDC-3042 Phase 1 dose-escalation data presented at AACR 2025 demonstrated a favorable…
Annualized recurring revenue (“ARR”) of $837 million, an increase of 4% year-over-yearTotal revenue of $210 million, up 3% year-over-year; Product…
This website uses cookies.